14966 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

have or will have obtained testimony on this problem from more expert witnesses than me. If the data are as I suggest, they will support greater controls for some of the drugs currently in Schedules III and IV.

BS:ck